Iterum Therapeutics plc
Iterum Therapeutics plc (ITRM) Revenue
Annual & quarterly revenue history · segment & region breakdown
ITRM · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsIterum Therapeutics plc trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from $0.00B in FY2024.
Revenue trend
2024 – 2016 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2024-12-31 | $0.00B | +$0.00B | — |
| 2023-12-31 | $0.00B | +$0.00B | — |
| 2022-12-31 | $0.00B | +$0.00B | — |
| 2021-12-31 | $0.00B | +$0.00B | — |
| 2020-12-31 | $0.00B | -$0.00B | -100.00% |
| 2019-12-31 | $0.00B | -$0.00B | -95.74% |
| 2018-12-31 | $0.00B | +$0.00B | +71.06% |
| 2017-12-31 | $0.00B | +$0.00B | — |
| 2016-12-31 | $0.00B | — | — |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Iterum Therapeutics plc receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Iterum Therapeutics plc reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Iterum Therapeutics plc's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
ITRM revenue · 4 questionsITRM's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from $0.00B in FY2024.
▸ Source: FMP · Iterum Therapeutics plc SEC filings · GAAP · Iterum Therapeutics plc SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026